Remove AFIB Remove Pulmonary Remove Stenosis
article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 1 These included one pseudoaneurysm, one PV stenosis and one hematoma.1

Ablation 105
article thumbnail

CardioSignal Looks to Expand CVD Detection through Patients Phones

CardiacWire

CardioSignal has already developed digital biomarkers for AFib and heart failure, while more solutions could be on the way for aortic stenosis, coronary artery disease, and pulmonary artery hypertension.

AFIB 75
article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

The VARIPULSE Platform is designed to enable pulmonary vein isolation with the versatility of a catheter loop, a simple generator user interface, and a mapping system that provides an intuitive, reproducible workflow with real-time visualization, contact indicator, and PF tagging mechanisms. In the U.S.,

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ).

article thumbnail

Supercharging the ECG: AI set to Revolutionize the Diagnostic Cardiology Market

DAIC

The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.

AFIB 105
article thumbnail

JACC: Advances Publishes New Science From AHA 2024

American College of Cardiology

New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry in coronary artery calcium (CAC) scans to predict atrial fibrillation (AFib); the role of treating hospitals in facilitating cardiac rehabilitation (CR); (..)